Printed from Voxsanity (voxsanity.com.au) — NCT06531824 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
You have been diagnosed with chronic kidney disease (CKD) that is at risk of getting worse, confirmed by blood and urine tests done at least 3 months apart.
Your kidney function test results fall into one of two ranges: either your kidneys are working at a low-to-moderate level (eGFR between 20 and 44), OR your kidneys are working at a moderate level (eGFR between 45 and 89) but your urine shows a significant amount of protein leaking through.
You are not currently required to take, or permanently unable to take, a specific type of blood pressure/kidney medication called an Aldosterone Synthase inhibitor or Mineralocorticoid Receptor Antagonist.
Who may not be able to join:
Your blood potassium level was found to be too high at your screening appointment.
Your liver enzyme levels (ALT or AST) were found to be significantly above the normal range at your screening appointment.
You have been diagnosed with liver cirrhosis (serious scarring of the liver).
You are currently on dialysis, have a working transplanted kidney, or have a living donor kidney transplant already planned.
You have started a new medication to suppress your immune system for a kidney condition within the last 60 days.
You are currently taking two different types of blood pressure medications that work on the same system in the body (known as dual RAS therapy).
You are currently taking a type of medication called a Mineralocorticoid Receptor Antagonist (for example, spironolactone, eplerenone, or finerenone).
You are currently taking a steroid hormone replacement medication called fludrocortisone or similar.
There are additional criteria not listed here (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Renal Research, Gosford, Gosford, New South Wales
1800271035
Port Macquarie Base Hospital (PMBH), Port Macquarie, New South Wales
1800271035
Flinders Medical Centre, Bedford Park, South Australia
1800271035
Eastern Health-Box Hill Hospital, Box Hill, Victoria
1800271035
Austin Health, Heidelberg Heights, Victoria
1800271035
St Vincent's Hospital Melbourne, Melbourne, Victoria
1800271035
Sunshine Hospital, St Albans, Victoria
1800271035
Macquarie University, New South Wales,
1800271035
Westmead Hospital, New South Wales,
1800271035
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT06531824
Sponsor: Boehringer Ingelheim
Phase: Phase 3
Status: Recruiting
Condition: Chronic Kidney Disease
Trial contact: 1-800-243-0127
More information: https://clinicaltrials.gov/study/NCT06531824
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
You have been diagnosed with chronic kidney disease (CKD) that is at risk of getting worse, confirmed by blood and urine tests done at least 3 months apart.
Your kidney function test results fall into one of two ranges: either your kidneys are working at a low-to-moderate level (eGFR between 20 and 44), OR your kidneys are working at a moderate level (eGFR between 45 and 89) but your urine shows a significant amount of protein leaking through.
You are not currently required to take, or permanently unable to take, a specific type of blood pressure/kidney medication called an Aldosterone Synthase inhibitor or Mineralocorticoid Receptor Antagonist.
Who may not be able to join:
Your blood potassium level was found to be too high at your screening appointment.
Your liver enzyme levels (ALT or AST) were found to be significantly above the normal range at your screening appointment.
You have been diagnosed with liver cirrhosis (serious scarring of the liver).
You are currently on dialysis, have a working transplanted kidney, or have a living donor kidney transplant already planned.
You have started a new medication to suppress your immune system for a kidney condition within the last 60 days.
You are currently taking two different types of blood pressure medications that work on the same system in the body (known as dual RAS therapy).
You are currently taking a type of medication called a Mineralocorticoid Receptor Antagonist (for example, spironolactone, eplerenone, or finerenone).
You are currently taking a steroid hormone replacement medication called fludrocortisone or similar.
There are additional criteria not listed here (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 15 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
🇦🇷 Argentina
🇦🇺 Australia
🇧🇪 Belgium
🇧🇷 Brazil
🇨🇦 Canada
🇨🇳 China
🇩🇰 Denmark
🇩🇪 Germany
🇮🇳 India
🇮🇹 Italy
🇯🇵 Japan
🇲🇾 Malaysia
🇲🇽 Mexico
🇳🇿 New Zealand
🇵🇹 Portugal
🇰🇷 South Korea
🇸🇪 Sweden
🇹🇼 Taiwan
🇬🇧 United Kingdom
🇺🇸 United States
9 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Time to first occurrence of the primary composite outcome of: (i) Kidney disease progression*; or (ii) Hospitalization for heart failure; or (iii) Cardiovascular death.
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.